用于肝脏、肾脏和胰腺移植的FK 506。
FK 506 for liver, kidney, and pancreas transplantation.
作者信息
Starzl T E, Todo S, Fung J, Demetris A J, Venkataramman R, Jain A
机构信息
Department of Surgery, University Health Center of Pittsburgh, Pennsylvania.
出版信息
Lancet. 1989 Oct 28;2(8670):1000-4. doi: 10.1016/s0140-6736(89)91014-3.
Abstract
FK 506 was given for immunosuppression in 14 liver recipients. The drug was used in the first 10 cases because the recipients under conventional immunosuppression had rejection, nephrotoxicity, or both. This salvage therapy was successful in 7 of the 10 attempts. 2 of the 10 patients in the original salvage group as well as 4 new patients underwent fresh orthotopic liver transplantation under FK 506 plus low-dose steroids from the outset. None of these 6 patients had rejection although 1 with preexisting cor pulmonale and coronary atherosclerosis died of a myocardial infarction. In addition, 2 of the 14 liver recipients were given cadaveric kidneys, either from the same donor or from a different donor, and a third was given a pancreas as well as a kidney from the liver donor. There were no rejections of the kidney and pancreas grafts, and serious side-effects were not encountered.
摘要
14例肝移植受者接受FK 506免疫抑制治疗。在前10例患者中使用该药物是因为接受传统免疫抑制治疗的受者出现了排斥反应、肾毒性或两者皆有。这种挽救治疗在10次尝试中有7次成功。最初挽救治疗组的10例患者中有2例以及4例新患者一开始就接受了FK 506加小剂量类固醇的原位肝移植。这6例患者均未发生排斥反应，尽管1例有慢性肺心病和冠状动脉粥样硬化的患者死于心肌梗死。此外，14例肝移植受者中有2例接受了来自同一供者或不同供者的尸体肾移植，第3例还接受了来自肝供者的胰腺和肾移植。肾和胰腺移植物均未发生排斥反应，也未出现严重的副作用。
相似文献
1
FK 506 for liver, kidney, and pancreas transplantation.用于肝脏、肾脏和胰腺移植的FK 506。
Lancet. 1989 Oct 28;2(8670):1000-4. doi: 10.1016/s0140-6736(89)91014-3.
2
Sirolimus-tacrolimus combination immunosuppression.西罗莫司-他克莫司联合免疫抑制
Lancet. 2000 Jan 29;355(9201):376-7. doi: 10.1016/S0140-6736(99)03882-9.
3
Mycophenolate mofetil in pancreas transplantation.霉酚酸酯在胰腺移植中的应用
Transplantation. 1998 Aug 15;66(3):318-23. doi: 10.1097/00007890-199808150-00007.
4
A multicenter, open-label, comparative trial of two daclizumab dosing strategies vs. no antibody induction in combination with tacrolimus, mycophenolate mofetil, and steroids for the prevention of acute rejection in simultaneous kidney-pancreas transplant recipients: interim analysis.一项多中心、开放标签、比较两种达利珠单抗给药策略与不使用抗体诱导剂联合他克莫司、霉酚酸酯和类固醇预防同期肾胰腺移植受者急性排斥反应的试验：中期分析。
Clin Transplant. 2002 Feb;16(1):60-8. doi: 10.1034/j.1399-0012.2002.00108.x.
5
Liver, kidney, and thoracic organ transplantation under FK 506.在使用FK506情况下的肝脏、肾脏及胸部器官移植。
Ann Surg. 1990 Sep;212(3):295-305; discussion 306-7. doi: 10.1097/00000658-199009000-00008.
6
Tacrolimus monotherapy following alemtuzumab induction in combined kidney-pancreas transplantation: results of a prospective randomized trial.在肾胰联合移植中，阿仑单抗诱导后使用他克莫司单药治疗：一项前瞻性随机试验的结果
Ann Transplant. 2012 Dec 31;17(4):45-51. doi: 10.12659/aot.883693.
7
Tacrolimus in pancreas transplantation: a multicenter analysis. Tacrolimus Pancreas Transplant Study Group.他克莫司在胰腺移植中的应用：一项多中心分析。他克莫司胰腺移植研究组。
Clin Transplant. 1997 Aug;11(4):299-312.
8
Rapamycin in combination with cyclosporine or tacrolimus in liver, pancreas, and kidney transplantation.雷帕霉素与环孢素或他克莫司联合用于肝脏、胰腺及肾脏移植。
Transplant Proc. 2003 May;35(3 Suppl):201S-208S. doi: 10.1016/s0041-1345(03)00231-8.
9
Weaning of immunosuppression in liver transplant recipients.肝移植受者免疫抑制的撤减
Transplantation. 1997 Jan 27;63(2):243-9. doi: 10.1097/00007890-199701270-00012.
10
Potential immunological advantage of intravenous mycophenolate mofetil with tacrolimus and steroids in primary deceased donor liver transplantation and live donor liver transplantation without antibody induction.在无抗体诱导的原发性脑死亡供体肝移植和活体供肝移植中，静脉注射霉酚酸酯联合他克莫司及类固醇的潜在免疫学优势
Liver Transpl. 2008 Feb;14(2):202-9. doi: 10.1002/lt.21348.
引用本文的文献
1
Bibliometric and LDA analysis of acute rejection in liver transplantation: Emerging trends, immunotherapy challenges, and the role of artificial intelligence.肝移植急性排斥反应的文献计量学与潜在狄利克雷分配分析：新趋势、免疫治疗挑战及人工智能的作用
Cell Transplant. 2025 Jan-Dec;34:9636897251325628. doi: 10.1177/09636897251325628. Epub 2025 Mar 28.
2
Lesson learnt from 60 years of liver transplantation: Advancements, challenges, and future directions.从60年肝移植中汲取的经验教训：进展、挑战与未来方向。
World J Transplant. 2025 Mar 18;15(1):93253. doi: 10.5500/wjt.v15.i1.93253.
3
Factors influencing intrapatient variability of tacrolimus and its association with 1-year post-transplant outcomes in pediatric liver transplant recipients.影响小儿肝移植受者他克莫司体内变异性的因素及其与移植后1年结局的关联
Front Pharmacol. 2024 Nov 21;15:1473891. doi: 10.3389/fphar.2024.1473891. eCollection 2024.
4
Mechanisms of Tolerance Induction in Liver Transplantation: Lessons Learned from Fetomaternal Tolerance, Autoimmunity and Tumor Immunity.肝移植中的耐受诱导机制：从胎母耐受、自身免疫和肿瘤免疫中获得的经验教训。
Int J Mol Sci. 2024 Aug 28;25(17):9331. doi: 10.3390/ijms25179331.
5
Animal models for transplant immunology: bridging bench to bedside.移植免疫学的动物模型：从实验室到临床的桥梁。
Clin Transplant Res. 2024 Dec 31;38(4):354-376. doi: 10.4285/ctr.24.0029. Epub 2024 Sep 5.
6
A review of landmark studies on maintenance immunosuppressive regimens in kidney transplantation.肾移植维持免疫抑制方案的里程碑式研究综述。
Asian Biomed (Res Rev News). 2024 Jun 28;18(3):92-108. doi: 10.2478/abm-2024-0015. eCollection 2024 Jun.
7
A descriptive study of the single-nucleotide polymorphisms known to affect the Tacrolimus trough concentration per dose, among a population of kidney failure patients in a tertiary hospital in Ghana.在加纳一家三级医院的肾衰竭患者人群中，对已知影响他克莫司每剂量血药谷浓度的单核苷酸多态性进行描述性研究。
BMC Res Notes. 2024 Jul 29;17(1):210. doi: 10.1186/s13104-024-06868-8.
8
Update on Maintenance Immunosuppression in Intestinal Transplantation.肠移植中维持性免疫抑制的最新进展。
Gastroenterol Clin North Am. 2024 Sep;53(3):493-507. doi: 10.1016/j.gtc.2023.12.007. Epub 2024 Jan 23.
9
Role of calcineurin in regulating renal potassium (K) excretion: Mechanisms of calcineurin inhibitor-induced hyperkalemia.钙调神经磷酸酶在调节肾脏钾（K）排泄中的作用：钙调神经磷酸酶抑制剂引起高钾血症的机制。
Acta Physiol (Oxf). 2024 Aug;240(8):e14189. doi: 10.1111/apha.14189. Epub 2024 Jun 11.
10
The Effect of Pringle Maneuver Applied during Living Donor Hepatectomy on the Ischemia-Reperfusion Injury Observed in the Donors and Recipients.活体肝移植术中应用Pringle手法对供体和受体缺血再灌注损伤的影响。
Medicina (Kaunas). 2024 Apr 18;60(4):649. doi: 10.3390/medicina60040649.
本文引用的文献
1
Pancreaticoduodenal transplantation in humans.人类胰十二指肠移植
Surg Gynecol Obstet. 1984 Sep;159(3):265-72.
2
Effect of a new immunosuppressive agent, FK 506, on heterotopic cardiac allotransplantation in the rat.新型免疫抑制剂FK 506对大鼠异位心脏同种异体移植的影响。
Transplant Proc. 1987 Feb;19(1 Pt 2):1284-6.
3
Renal transplantation in baboons under FK 506.在使用FK506的情况下狒狒的肾移植
Surgery. 1989 Aug;106(2):444-50; discussion 450-1.
4
Effects of combination treatment with FK506 and cyclosporine on survival time and vascular changes in renal-allograft-recipient dogs.FK506与环孢素联合治疗对犬同种异体肾移植受者存活时间及血管变化的影响
Transplantation. 1989 Aug;48(2):193-7. doi: 10.1097/00007890-198908000-00003.
5
6
FK-506, a novel immunosuppressant isolated from a Streptomyces. II. Immunosuppressive effect of FK-506 in vitro.FK-506，一种从链霉菌中分离出的新型免疫抑制剂。II. FK-506的体外免疫抑制作用。
J Antibiot (Tokyo). 1987 Sep;40(9):1256-65. doi: 10.7164/antibiotics.40.1256.
7
Pathological studies in canine and baboon renal allograft recipients immunosuppressed with FK-506.对用FK-506免疫抑制的犬和狒狒肾移植受者的病理学研究。
Transplant Proc. 1987 Oct;19(5 Suppl 6):98-9.
8
Heterotopic heart transplantation in the rat receiving FK-506 alone or with cyclosporine.单独接受FK-506或与环孢素联合使用时大鼠的异位心脏移植
Transplant Proc. 1987 Oct;19(5 Suppl 6):71-5.
9
Orthotopic liver transplantation in dogs receiving FK-506.接受FK-506的犬原位肝移植
Transplant Proc. 1987 Oct;19(5 Suppl 6):64-7.
10
Canine kidney transplantation with FK-506 alone or in combination with cyclosporine and steroids.单独使用FK-506或联合环孢素和类固醇进行犬肾移植。
Transplant Proc. 1987 Oct;19(5 Suppl 6):57-61.
Zotero 插件